Tempest Therapeutics Announces Strategic Partnership with Roche
Tempest Therapeutics, Inc. (NASDAQ: TPST), a dynamic clinical-stage biotechnology firm, has recently unveiled an exciting partnership with Roche, aimed at promoting the evaluation of amezalpat (also known as TPST-1120). This collaboration specifically targets the use of amezalpat alongside atezolizumab (Tecentriq) and bevacizumab in a crucial pivotal Phase 3 trial aimed at first-line treatment for hepatocellular carcinoma (HCC), also known as liver cancer.
Details of the Agreement
This agreement marks a significant milestone for Tempest, as Roche will provide atezolizumab on a global scale while Tempest will spearhead the management of this pivotal clinical study. Their joint efforts will stem from a previous collaboration wherein amezalpat was assessed alongside the current standard of care—atezolizumab and bevacizumab—in a randomized Phase 1b/2 study involving first-line HCC patients. Tempest maintains exclusive development and commercial rights to amezalpat, reinforcing its position in the cancer treatment landscape.
CEO Comments on the Collaboration
Stephen Brady, the president and CEO of Tempest, expressed enthusiasm regarding this partnership. He stated, "We're thrilled to announce this agreement that supports the advancement of amezalpat into a pivotal study and underscores both Tempest’s and Roche’s commitment to pioneering cancer therapies for patients. We believe that the combination therapy has significant potential to enhance treatment outcomes for those battling liver cancer." He highlighted the encouraging Phase 2 data which indicates transformative potential for improving first-line liver cancer treatment through this collaboration.
Reaffirming Clinical Benefits
In the earlier stages of the trial, Tempest reported impressive survival data showcasing a six-month increase in median overall survival for patients undergoing the combination therapy compared to those receiving the standard care regimen of atezolizumab and bevacizumab. This survival advantage was particularly notable across key subpopulations, reiterating the compound's clinical value. Moreover, findings suggested notable efficacy regardless of patients' PD-L1 status and in those with immune excluded and immune desert tumors.
Plans for Phase 3 Study
In its meeting with the FDA, Tempest secured an agreement regarding the Phase 3 study's design, which includes the amezalpat dosage and a primary endpoint focused on overall survival. Additionally, the statistical plan was discussed, which may potentially accelerate the timeline to the primary analysis of the study by eight months. The company is gearing up for the commencement of this pivotal Phase 3 trial, anticipated to begin in the first quarter of 2025.
Overview of the TPST-1120-301 Study
The upcoming Phase 3 investigation is laid out to be a global, blinded, and randomized study. It will compare the combination of amezalpat plus atezolizumab and bevacizumab against the standard of care—atezolizumab plus bevacizumab—in patients diagnosed with unresectable or metastatic HCC. With a robust go-ahead timeline from the FDA, the groundwork is set for advancing innovative treatments for liver cancer.
About Amezalpat (TPST-1120)
Amezalpat is classified as an oral, small molecule, selective PPAR? antagonist. Clinical studies indicate it operates by directly targeting tumor cells while also modulating the immune suppressive cells and influencing angiogenesis within the tumor microenvironment. The ongoing global randomized Phase 1b/2 study has shown amezalpat to significantly outperform standard treatments regarding various study endpoints, particularly overall survival rates.
About Tempest Therapeutics
Tempest Therapeutics is dedicated to developing a diverse array of small molecule therapy candidates, focusing on tumor-targeted and immune-mediated approaches. Their novel methods are under ongoing research, progressing from initial studies to advanced phases of trials. Based in Brisbane, California, Tempest Therapeutics continuously seeks to innovate and expand its impact in the field of oncology.
Frequently Asked Questions
What is the main objective of the partnership between Tempest and Roche?
The partnership aims to advance the evaluation of amezalpat in combination with other therapies for treating hepatocellular carcinoma in a pivotal Phase 3 trial.
What are the expected outcomes of the Phase 3 trial?
The Phase 3 trial aims to demonstrate the efficacy of amezalpat combined with atezolizumab and bevacizumab in improving overall survival rates for patients with liver cancer.
What does amezalpat target in cancer treatment?
Amezalpat targets tumor cells directly and modulates immune suppressive cells and angiogenesis in the tumor microenvironment.
When is the Phase 3 study expected to begin?
The study is expected to commence in the first quarter of 2025, following the recent agreement with the FDA.
Where is Tempest Therapeutics located?
Tempest Therapeutics is headquartered in Brisbane, California, focusing on innovative cancer treatment solutions.
